移植后FDG PET/CT在多发性骨髓瘤中的预后价值
该回顾性研究分析了229例接受自体干细胞移植的多发性骨髓瘤患者移植后约100天FDG PET/CT的预后影响。异常PET表现与更短的无进展时间和总生存期显著相关,且校正疾病缓解和其他预后变量后仍具独立预后意义。
要点
- 移植后100天PET/CT异常提示更短TTP和OS。
- PET阳性者中位TTP为12.4个月,阴性者为24个月。
- PET阳性者中位OS为46个月,阴性者为99个月。
核心结论
- ASCT后约100天PET/CT异常可预测更短的无进展时间和总生存期。
- 校正疾病缓解和其他预后变量后,PET/CT的预后意义仍保留。
研究设计与样本
- 回顾性分析229例接受自体干细胞移植的多发性骨髓瘤患者的PET/CT扫描。
- 扫描时间在移植后约100天,分析PET/CT结果与TTP和OS的相关性。
主要发现
- 整个队列中位OS为61.5个月(95%CI 49-75),中位TTP为18.5个月(95%CI 15.4-21.8)。
- PET阳性患者中位TTP为12.4个月,PET阴性患者为24个月(P < .0001)。
- PET阳性组中位OS为46个月,PET阴性组为99个月(P < .0001)。
临床怎么用
- 移植后约100天PET/CT异常结果可用于识别TTP和OS较短的高危患者。
局限性
- 研究为回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a heterogeneous disease that may be evaluated by a broad array of imaging and laboratory techniques to measure disease activity and predict prognosis. Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning has been shown to be predictive of patient outcomes throughout the disease course. We sought to corroborate these findings by examining the prognostic impact of PET/CT scanning in the posttransplant setting. We retrospectively analyzed PET/CT scans in 229 MM patients receiving an autologous stem cell transplant (ASCT) near day 100, and correlated these findings with time to progression(TTP) and overall survival (OS) to assess the impact of day 100 PET/CT scan findings as an independent prognostic factor. The median OS for the entire cohort was 61.5 months (95% confidence interval [CI], 49-75) and the median TTP was 18.5 months (95% CI, 15.4-21.8). Among patients with abnormal day 100 PET findings (PET+), median TTP was 12.4 months vs 24 months among those with normal PET findings (PET-) (P < .0001). The median OS in the PET+ group was 46 months compared with 99 months in the PET- group (P < .0001). We conclude that an abnormal PET/CT scan near day 100 post-ASCT is predictive of shorter TTP and OS, with prognostic significance retained after adjusting for disease response and other prognostic variables in MM.
引用
- Kaddoura M, Dingli D, Buadi FK, et al. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv. 2021. PMID: 34242392. doi:10.1182/bloodadvances.2020004131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。